Duska Therapeutics

Duska Therapeutics, Inc. (Duska or the Company) is a publicly-traded company that develops new medicines, medical devices, and diagnostics based on adenosine-5’ triphosphate (ATP) and P2 receptor-related technologies. In addition to ATPace^TM (adenosine triphosphate injection) for the acute treatment and diagnosis of certain cardiac arrhythmias, the Company’s drug and medical device programs target the enhancement of sperm motility, chronic obstructive pulmonary disorder, and mitigation of the toxic effects of radiation exposure.

Duska is developing a portfolio of proprietary products. One of the Company’s strategies is to in-license and develop clinical stage drug candidates that target pharmaceutical markets that can be more rapidly commercialized. Duska’s experienced management team conducts whatever clinical trials may be necessary to establish evidence of safety and efficacy. The Company may seek partnerships with pharmaceutical and biotechnology companies for late-stage development and marketing of product candidates.

Duska Therapeutics, Inc.’s common stock is traded on the Over-The-Counter bulletin board securities market, symbol “DSKA.OB”.